This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Quadrivalent Influenza Vaccines

NEW YORK, Feb. 18, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Quadrivalent influenza vaccines

http://www.reportlinker.com/p0961707/MarketVIEW-Quadrivalent-influenza-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Annual seasonal influenza epidemics typically affect 5-15% of the population with mainly upper respiratory tract infections. On a global basis around 3-5 million cases of severe illness are estimated each year with an associated 250,000 - 500,000 deaths (WHO figures). Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Recommended groups for influenza vaccination are usually those most vulnerable and include the elderly, very young and those with underlying chronic diseases. In the US, influenza vaccination recommendations now include every person >6 mos. Influenza vaccines are predominantly of the trivalent inactivated format (TIV) although latest advances include the addition of another B virus strain to form quadrivalent (QIV) vaccines . 

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Quadrivalent influenza (QIV) vaccines across major Western and 20 emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. 3 possible uptake scenarios for QIVs are included based upon the level of populations targeted. Estimated potential revenues for the main competitors are also included along with a review of their development status to date. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL 

Executive summaryQuadrivalent influenza vaccines: key model outputsSeasonal influenza vaccine(s): predicted market to 2030 (GLOBAL)Seasonal influenza vaccine(s): predicted volume to 2030 (GLOBAL)Seasonal influenza vaccine(s): predicted market by country to 2030 (WEST)Seasonal influenza vaccine(s): predicted market by country to 2030 (ROW)QIV vaccines: possible uptake scenarios (doses 000s)QIV vaccines: competitor revenues per uptake scenario (2020)Quadrivalent influenza vaccines: background/rationale for developmentBrief background to seasonal influenzaInfluenza virus typesAntigenic evolution of influenza virusesFocus on the influenza B virusInfluenza B virus lineagesInfluenza B virus prevalenceInfluenza B virus prevalence (US), 2001 – 2011Influenza B virus prevalence (EU), 2001 – 2011Influenza B virus diseaseInfluenza B virus and vaccinationInfluenza season and B lineage (US), 2001 – 2011Influenza B Strains recommended for inclusion in recent yearsInfluenza season and B lineage (EU), 2001 – 2011The need for a quadrivalent (QIV) influenza vaccineQuestions raised by QIV vaccinesQIV vaccines: manufacturing issuesQIV formats previously under considerationQuadrivalent influenza vaccines: summary of competitor activity to dateAZ/MedImmune: QIV vaccine developmentMedImmune: Overview of QIV studiesMedImmune: chronology of QIV regulatory reviewMedImmune: Phase II/III data 18-49 yrsMedImmune: Phase III data 2-17 yrsMedImmune: further studiesSanofi Pasteur: QIV vaccine developmentSanofi Pasteur: Phase II data – adultsSanofi Pasteur: Phase II data > 65 yrsSanofi Pasteur: Phase III studies/notesGSK: QIV vaccine developmentNovartis Vaccines: QIV vaccine developmentQuadrivalent influenza vaccines: modelling potential demand/commercial valueCountries included in analysisPopulations modelled to 2030Modelling strategy: segments/countriesROW Countries modelled: summary of schedule/volumesWest Countries modelled: summary of schedule/volumesCoverage assumptions per country/target group (West)Coverage assumptions per country/target group (ROW)Private sector growth rates applied: LOPrivate sector growth rates applied: HIModelling strategy: TIV pricingModelling strategy: QIV pricingQIV vaccines: estimated launch datesQIV vaccines: possible uptake scenariosQIV vaccines: possible uptake scenarios/market shareQIVs: competitor market share estimates: uptake scenarios 1 & 2QIVs: competitor market share estimates: uptake scenarios 3Commercial model: caveatsReferences/bibliographyAbout VacZine AnalyticsDisclaimerPAGES: 72 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetQIV analysis =>CHARTS QIV competitorsCHARTS QIV VOL scenariosSCENARIO 1SCENARIO 2SCENARIO 3Demand analysesCHARTS ALL VAL VOLCHARTS WEST VALCHARTS ROW VOLGrand value ROW (pub & priv)Grand value WEST (pub & priv)TIV pricing summaryGrand volume ROW (pub & priv)Grand volume WEST (pub & priv)Total volume sum (private ROW)Total volume sum (private West)Total volume sum (public ROW)Total volume sum (public West)Volume summary (infant risk)Volume summary (2-19 yrs risk)Volume summary (19-65 yrs risk)Volume summary (> 65 yrs)Private sector growth ratesCountry worksheets (all segments)USACanadaUnited KingdomFranceGermanyItalyArgentinaAustraliaBrazilChinaHong KongIndiaIndonesiaJapanMacauMalaysiaMexicoMongoliaNepalPakistanPhilippinesRussiaSouth KoreaTaiwanThailandVietnamResources =>>Country actual volume data (West)Country actual volume data (ROW)Schedules influenzaPopulation databases% privateBack pageWorksheets = >120 interconnected

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs